Aptose Biosciences Inc. (APTOF) presents a deeply negative liquidation recovery posture as of March 31, 2026. The company is a pre-revenue clinical-stage oncology firm with no product sales, no inventory, and no meaningful tangible asset base beyond cash. Under a liquidation lens, the balance sheet is dominated by liabilities with negligible recoverable assets. Reported cash and restricted cash stood at $4.1 million at quarter-end, which at 100% recovery represents the entirety of liquidation-recoverable assets. Against this, the company reported a shareholders' deficit of $34.7 million (widened from $27.2 million at December 31, 2025, an increase of $7.5 million in one quarter), a working capital deficiency of negative $5.1 million (versus negative $2.9 million at December 31, 2025), and an accumulated deficit of $574.1 million. The liability stack is supported almost entirely by advances from Hanmi Pharmaceutical under the Second Amended Facility Agreement — up to $11.1 million in uncommitted advances, of which $7.1 million had been drawn as of the filing date, with principal repayable August 31, 2028. These advances are not subordinated and would sit senior to equity in any wind-up. Operating cash burn was $5.8 million in Q1 2026, roughly double the $2.8 million burn in Q1 2025, driven by escalating TUSCANY trial costs ($2.9 million in tuspetinib program costs versus $1.5 million prior year) and elevated G&A from arrangement-related professional fees. The company's sole liquidity source is the uncommitted Hanmi facility, which Hanmi may cancel at any time without notice. Management has explicitly disclosed substantial going concern doubt. The Hanmi Plan of Arrangement, if closed by June 30, 2026 at C$2.41 per share, would represent the only viable recovery mechanism for equity holders; absent that close, the company discloses imminent bankruptcy risk. Intangible assets including the tuspetinib license and associated IP carry zero recovery value under the liquidation lens. The Luxeptinib program has been returned to CrystalGenomics as of April 30, 2026, eliminating any residual asset value there. The MFFAIS liquidation value estimate of negative $8.6 million is consistent with the balance sheet data, though actual recovery could be worse given the face-value treatment of the Hanmi debt obligations. Filing discusses the Hanmi facility and arrangement agreement extensively in MD&A but the only XBRL tag emitted in this 10-Q is shares outstanding — the balance sheet, debt obligations, and facility draws are not separately tagged in XBRL beyond what is referenced in narrative prose.
▼ Community Notes